Trial Profile
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 14 Nov 2023 Planned End Date changed from 30 Jun 2023 to 9 Aug 2024.
- 01 Jul 2022 Planned End Date changed from 30 Jun 2022 to 30 Jun 2023.
- 01 Jul 2022 Planned primary completion date changed from 30 Jun 2022 to 30 Jun 2023.